|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Conclusions</b>: These findings support the hypothesis that ART affects cancer and endothelial cells by targeting the auto-paracrine effects of VEGF to suppress mitochondrial biogenesis, angiogenesis, and migration between cancer cells and endothelial cells.
|
31588240 |
2019 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>Purpose:</b> VEGF-targeted therapies have modest efficacy in cancer patients, but acquired resistance is common.
|
28855350 |
2017 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
8-Cl-cAMP treatment caused in the three cancer cell lines a significant dose- and time-dependent inhibition in the expression of various endogenous autocrine growth factors, such as transforming growth factor alpha, amphiregulin, and CRIPTO, and of two angiogenic factors, such as vascular endothelial growth factor and basic fibroblast growth factor, at both the mRNA and protein levels.
|
9815703 |
1997 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Cancer cell lines with high constitutive levels of HIF-1alpha protein were found to produce higher basal levels of VEGF.
|
12499918 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer treatment regimens combining anti-VEGF and anti-Ang-2 agents may be an effective strategy to improve the efficacy of current anti-VEGF therapies.
|
20501615 |
2010 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Cancer-associated fibroblasts (CAFs) isolated from murine lung adenocarcinomas secreted abundant VEGF and enhanced tumor cell invasion in coculture studies.
|
21115742 |
2011 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Malignant tumors and chronic inflammatory diseases induce angiogenesis by overexpressing vascular endothelial growth factor A (VEGF-A/VPF).
|
21411713 |
2011 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VEGF expression in advanced primary cancers was greater (P = 0.002) and, in early cancers, marginally greater (P = 0.05) than adjacent normal mucosa.
|
10213212 |
1999 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) protein expression has shown to be strictly associated with neovascularization both in human cancer and in various type of preinvasive lesions.
|
10373662 |
1999 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF occurs also in canine tumors in similar relative quantities as in human malignancies.
|
10661874 |
1999 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) has potent angiogenic activity and has been identified in a wide variety of malignancies, including head and neck squamous cell carcinoma (HNSCC).
|
10779196 |
2000 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a key angiogenic molecule that plays an important role in the growth and metastasis of many types of human cancer, including pancreatic adenocarcinoma.
|
11358838 |
2001 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is a potent angiogenic factor associated with the growth and metastasis of various cancers and plays a prominent role in vesical angiogenesis regulation.
|
11483411 |
2001 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
VEGF has been found to be expressed in several different types of tumors, and it may contribute to the progression of malignant tumors.
|
11806643 |
2002 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) plays a critical role during normal embryonic angiogenesis and also in the pathological angiogenesis that occurs in a number of diseases, including cancer.
|
12177445 |
2002 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) has potent angiogenic activity and has been identified in a wide variety of malignancies, including pancreatic carcinoma.
|
12298426 |
2002 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is one of the most potent angiogenic growth factors and its expression is correlated with MVD (microvascular density) in malignant tumors, including pancreatic adenocarcinoma.
|
12553038 |
2003 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is regulated by the hypoxia-inducible factor 1 (HIF1) pathway and is implicated in tumor progression and patient survival in many types of cancer.
|
15086970 |
2004 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) and interleukin-8/CXCL8 (IL-8) are prominent pro-angiogenic and pro-metastatic proteins that represent negative prognostic factors in many types of cancer.
|
15256456 |
2004 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF)-A is an important angiogenic cytokine in cancer and pathological angiogenesis and has been related to the antiangiogenic activity of dopamine in endothelial cells.
|
15817666 |
2005 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) upregulation is induced by many receptor and intracellular oncogenic proteins commonly activated in cancer, rendering molecular targeting of VEGF expression a complex challenge.
|
16007214 |
2005 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) promotes angiogenesis and is associated with the invasion and metastasis of malignant tumors.
|
16040218 |
2005 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF, namely VEGF-A) is an angiogenic polypeptide and VEGF-C is a lymphangiogenic polypeptide that has been implicated in cancer growth, invasion and metastasis.
|
16109537 |
2005 |
|
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
VEGF may constitute a novel therapeutic target for antiangiogenic cancer therapy.
|
16525667 |
2006 |
|
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Vascular endothelial growth factor (VEGF) is the predominant pro-angiogenic cytokine in human malignancy, and its expression correlates with disease recurrence and poor outcomes in patients with colorectal cancer.
|
16685275 |
2006 |